Thioridazine interferences with imipramine metabolism and measurement
- PMID:8946674
- DOI: 10.1097/00007691-199612000-00018
Thioridazine interferences with imipramine metabolism and measurement
Abstract
A case is presented in which toxic concentrations of imipramine (Tofranil) resulted from the co-administration of low-dose thioridazine (Mellaril). This probably occurred in an individual with genetically reduced capacity for oxidative drug metabolism, specifically via thioridazine's interference with the hepatic cytochrome P450IID6 isoenzyme (CYP2D6). In addition, coelution of thioridazine and its metabolites resulted in false elevations of imipramine and desipramine as measured by a common high-performance liquid chromatography (HPLC) method (cyanopropyl column). In contrast, an enzyme immunoassay (Abbott TDxFLx) and a second reference HPLC method (silica column) accurately resolved the analytes. This combination of psychiatric drugs is not uncommon in the pediatric population and is one of which both clinicians and laboratorians need to be aware. To the author's knowledge, this is the first report of interferences of thioridazine with both the metabolism and measurement of imipramine in a pediatric patient.
Similar articles
- Paroxetine shifts imipramine metabolism.Albers LJ, Reist C, Helmeste D, Vu R, Tang SW.Albers LJ, et al.Psychiatry Res. 1996 Jan 31;59(3):189-96. doi: 10.1016/0165-1781(95)02822-6.Psychiatry Res. 1996.PMID:8930024
- Association of graded allele-specific changes in CYP2D6 function with imipramine dose requirement in a large group of depressed patients.Schenk PW, van Fessem MA, Verploegh-Van Rij S, Mathot RA, van Gelder T, Vulto AG, van Vliet M, Lindemans J, Bruijn JA, van Schaik RH.Schenk PW, et al.Mol Psychiatry. 2008 Jun;13(6):597-605. doi: 10.1038/sj.mp.4002057. Epub 2007 Jul 31.Mol Psychiatry. 2008.PMID:17667959
- Pharmacokinetics and metabolism of thioridazine during co-administration of tricyclic antidepressants.Daniel WA, Syrek M, Haduch A, Wójcikowski J.Daniel WA, et al.Br J Pharmacol. 2000 Sep;131(2):287-95. doi: 10.1038/sj.bjp.0703540.Br J Pharmacol. 2000.PMID:10991922Free PMC article.
- Tricyclic-resistant depression: treatment resistance or inadequate treatment?Lydiard RB.Lydiard RB.J Clin Psychiatry. 1985 Oct;46(10):412-7.J Clin Psychiatry. 1985.PMID:3900051Review.
- Pharmacologic treatment of psychiatric and neurodevelopmental disorders in children and adolescents (Part 1).McDaniel KD.McDaniel KD.Clin Pediatr (Phila). 1986 Feb;25(2):65-71. doi: 10.1177/000992288602500201.Clin Pediatr (Phila). 1986.PMID:2417773Review.
Cited by
- Potent inhibition of CYP2D6 by haloperidol metabolites: stereoselective inhibition by reduced haloperidol.Shin JG, Kane K, Flockhart DA.Shin JG, et al.Br J Clin Pharmacol. 2001 Jan;51(1):45-52. doi: 10.1046/j.1365-2125.2001.01313.x.Br J Clin Pharmacol. 2001.PMID:11167668Free PMC article.
- Clinical pharmacokinetics of drugs used to treat urge incontinence.Guay DR.Guay DR.Clin Pharmacokinet. 2003;42(14):1243-85. doi: 10.2165/00003088-200342140-00004.Clin Pharmacokinet. 2003.PMID:14606931Review.
- Thioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype.Berecz R, de la Rubia A, Dorado P, Fernández-Salguero P, Dahl ML, LLerena A.Berecz R, et al.Eur J Clin Pharmacol. 2003 May;59(1):45-50. doi: 10.1007/s00228-003-0576-4. Epub 2003 Mar 28.Eur J Clin Pharmacol. 2003.PMID:12682803Clinical Trial.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources